Drug intelligence / Profile preview

CND319

Development stage: Phase 1
Lead developer: Candid Therapeutics
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

CND319 is a trispecific antibody developed by Candid Therapeutics. It is designed to simultaneously target CD19 and CD20 antigens on B-cell subtypes and engage CD3 on T cells. The drug acts as a modulator of these targets, aiming to deplete or modulate B cells implicated in autoimmune diseases by recruiting T cell-mediated cytotoxicity against B cells expressing both CD19 and CD20. As of June 2025, it is in preclinical development for autoimmune diseases[1][2][3][4].

Targets

CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on CND319.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CND319.

Explore the full profile